Synergistic Anticancer Effects of Gemcitabine with Pitavastatin on Pancreatic Cancer Cell Line MIA PaCa-2 in vitro and in vivo

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with an overall 5-year survival rate of 9.3%, and this malignancy is expected to become the second leading cause of cancer-related death by 2030. Gemcitabine resistance develops within weeks of PDAC patient’s chemo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Manag Res
Main Authors: Chen, Ya-Hui, Chen, Yi-Chun, Lin, Chi-Chen, Hsieh, Yao-Peng, Hsu, Chien-Sheng, Hsieh, Ming-Chia
Formato: Artigo
Idioma:Inglês
Publicado em: Dove 2020
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7306478/
https://ncbi.nlm.nih.gov/pubmed/32606957
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S247876
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados